Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Protemix Receives 2005 Frost & Sullivan Award

Protemix Receives 2005 Frost & Sullivan Excellence in Research Award in Recognition of the Company's Achievements in Field of Metabolic Diseases

SAN DIEGO & AUCKLAND, New Zealand-- Frost & Sullivan has named Protemix Corporation the recipient of its Excellence in Research of the Year Award in the field of therapeutics for metabolic disorders/diseases. The global consulting company cited the potential for Protemix drug candidates to improve health outcomes for patients with diabetic complications such as diabetic heart disease and other diabetes-induced organ damage.

Each year, Frost & Sullivan presents this Award to a company that has carried out new disruptive research; and has, in general, a strong commitment to research and development. This Award recognizes a company's research and development program that has or is expected to bring significant contributions to the industry in terms of adoption, change and competitive posture. The Award also recognizes the overall research excellence of a company as well as its commitment towards differentiating itself based on science-backed services or solutions.

"Protemix's model-based proteomics approach has led to a better understanding of both molecular targets and drug leads. This really forms the core of its discovery of new drug candidates for diabetes and other disorders," says Frost & Sullivan Research Analyst Sangeetha Prabakar.

Prof. Garth Cooper, New Zealand's leading biochemist and his team, based at the University of Auckland, led Protemix's research. Through their efforts, the company has developed an extensive pipeline of diabetes-related drug candidates based on novel insights regarding potential mechanisms for diabetes-induced health complications including diabetic heart disease. These drug candidates each address unique aspects of disease mechanisms (atherosclerosis, hypertension, and obesity) responsible for type II diabetes-induced organ damage.

The company's lead compound is Laszarin(TM), an orally active small molecule drug that is a potentially significant treatment option for diabetic heart failure -- generally fatal complication associated with type II diabetes for which current treatment options are relatively ineffective. Protemix researchers' discovery that the microvascular and macrovascular complications seen in diabetes and diabetic heart disease are in part caused by copper overload, has led to the belief that administration of antagonists can regulate copper. Laszarin(TM) acts by limiting cooper content and the production of superoxide free radicals, thus arresting and reversing the progress of diabetic complications, which has already been demonstrated in animals and humans with respect to reducing abnormal heart size and/or improving heart function.

Laszarin(TM) is currently the subject of a Phase 2b clinical trial being conducted in New Zealand and Australia. The U.S. Food and Drug Administration has granted this drug candidate Fast Track Status -- the first drug candidate from a New Zealand company to receive such designation.

Protemix has also achieved other major research breakthroughs.

For instance, by understanding the insulin signal transduction pathway, EN122004, a peptide hormone, was identified as a potential treatment for insulin resistance in type II diabetes and its associated conditions. By identifying the mechanism that causes alcohol-mediated liver tissue damage, a reduction in the levels of the hormone adipoenectin, Protemix found that the administration of glycosylated adipoenectin, of which their drug candidate PX811013 is a form, could reverse the liver damage and restore liver function.

"We are very pleased to gain recognition for Protemix's ground-breaking research through this prestigious Award," commented Protemix Chief Executive Officer, Larry Ellingson.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 100 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics and demographics. For more information, visit

About Protemix

Protemix is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel drugs for the prevention and treatment of diabetes, cardiovascular disease and metabolic diseases. The company was founded in Auckland, New Zealand and directs operations from offices in San Diego, California and Auckland, and research facilities located within the University of Auckland. The company's most advanced product, Laszarin(TM), is currently completing Phase II trials for the treatment of heart failure in diabetes patients and has received fast track status from the U.S. Food and Drug Administration for that indication. For more information on Protemix, please visit the company's website at

© Scoop Media

Business Headlines | Sci-Tech Headlines


Reserve Bank: Policy Lessons From A Year Of Covid-19

The Reserve Bank of New Zealand – Te Pūtea Matua was in a sound position to continue to meet its mandate in the face of the COVID-19 induced economic shock. However, we must continue to transform so as to remain relevant and effective in addressing longer-term challenges, Reserve Bank Governor Adrian Orr said... More>>

Transport Industry Association: Feb 2021 New Vehicle Registrations Strongest On Record

Motor Industry Association Chief Executive David Crawford says that the February 2021 figures are the strongest for the month of February ever. Registrations of 12,358 were 8.0% up on February 2020. Year to date the market is up 7.1% (1,735 units) compared to the first two months of 2020... More>>

Paymark: Lockdown Equals Slowdown For Some

The three days of lockdown for Auckland earlier this month made a clear impression on our retail spending figures. While only Auckland moved into Level 3 lockdown, the impact was felt across the country, albeit at different levels. Looking at the ... More>>

Infrastructure Commission: Te Waihanga Releases Report On Water Infrastructure

The New Zealand Infrastructure Commission, Te Waihanga’s latest discussion document highlights the importance of current reforms in the water sector. Its State of Play discussion document about water infrastructure is one of a series looking at the ... More>>

OECD: Annual Inflation Picks Up To 1.5% In January 2021 While Euro Area Records Sharp Increase To 0.9%

Annual inflation in the OECD area picked up to 1.5% in January 2021, compared with 1.2% in December 2020. Following a rebound between December and January, the annual decline in energy prices was less pronounced in January (minus 3.9%) than in December... More>>

Hemp Industries Association: Could The Next Team NZ Boat Be Made Entirely Of Hemp?

With The America’s Cup due to start in a few days’ time, innovators from a very different sphere have been wondering how long it could be before New Zealand could be competing in a boat entirely built from hemp, with the crew eating high-energy, nutritious hemp-infused foods and wearing high-performance hemp kit..? More>>

ACT: Matariki Almost A Half Billion Dollar Tax On Business

“Official advice to the Government says an extra public holiday at Matariki could cost almost $450 million,” ACT Leader David Seymour can reveal. “This is a perfect example of the Prime Minister doing what’s popular versus what’s responsible. ... More>>

Genesis: Assessing 6,000 GWh Of Renewable Generation Options For Development By 2025

Genesis is assessing 6,000 GWh of renewable generation options for development after starting a closed RFP process with 11 partners. Those invited to participate offer a range of technologies as Genesis continues to execute its Future-gen strategy to ... More>>